MX2023007507A - Vectores auxiliares adenovirales del serotipo 35. - Google Patents
Vectores auxiliares adenovirales del serotipo 35.Info
- Publication number
- MX2023007507A MX2023007507A MX2023007507A MX2023007507A MX2023007507A MX 2023007507 A MX2023007507 A MX 2023007507A MX 2023007507 A MX2023007507 A MX 2023007507A MX 2023007507 A MX2023007507 A MX 2023007507A MX 2023007507 A MX2023007507 A MX 2023007507A
- Authority
- MX
- Mexico
- Prior art keywords
- serotype
- auxiliary vectors
- helper
- vectors
- adenoviral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063129346P | 2020-12-22 | 2020-12-22 | |
| US202163215360P | 2021-06-25 | 2021-06-25 | |
| PCT/US2021/064954 WO2022140605A2 (en) | 2020-12-22 | 2021-12-22 | Adenoviral serotype 35 helper vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007507A true MX2023007507A (es) | 2023-09-08 |
Family
ID=82158498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007507A MX2023007507A (es) | 2020-12-22 | 2021-12-22 | Vectores auxiliares adenovirales del serotipo 35. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240301362A1 (https=) |
| EP (1) | EP4267159A4 (https=) |
| JP (1) | JP2024501841A (https=) |
| KR (1) | KR20230144530A (https=) |
| AU (1) | AU2021410006A1 (https=) |
| CA (1) | CA3204988A1 (https=) |
| IL (1) | IL303901A (https=) |
| MX (1) | MX2023007507A (https=) |
| TW (1) | TW202242119A (https=) |
| WO (1) | WO2022140605A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024006319A1 (en) * | 2022-06-29 | 2024-01-04 | Ensoma, Inc. | Adenoviral helper vectors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001079471A2 (en) * | 2000-04-12 | 2001-10-25 | Dana-Farber Cancer Institute | Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same |
| US20040203133A1 (en) * | 2003-01-07 | 2004-10-14 | Anja Ehrhardt | Helper dependent adenoviral vector system and methods for using the same |
| WO2005012537A2 (en) * | 2003-07-25 | 2005-02-10 | Genvec, Inc. | Adenoviral vector-based vaccines |
| ES2337973B8 (es) * | 2008-05-16 | 2011-07-21 | Proyecto De Biomedicina Cima, S.L. | Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad. |
| IL239344B2 (en) * | 2012-12-12 | 2024-06-01 | Broad Inst Inc | Systems engineering, methods and optimal guiding components for sequence manipulation |
| US20170037431A1 (en) * | 2014-05-01 | 2017-02-09 | University Of Washington | In vivo Gene Engineering with Adenoviral Vectors |
| SG11202111943UA (en) * | 2019-07-02 | 2021-11-29 | Hutchinson Fred Cancer Res | Recombinant ad35 vectors and related gene therapy improvements |
-
2021
- 2021-12-22 MX MX2023007507A patent/MX2023007507A/es unknown
- 2021-12-22 JP JP2023539336A patent/JP2024501841A/ja active Pending
- 2021-12-22 CA CA3204988A patent/CA3204988A1/en active Pending
- 2021-12-22 EP EP21912183.7A patent/EP4267159A4/en not_active Withdrawn
- 2021-12-22 IL IL303901A patent/IL303901A/en unknown
- 2021-12-22 AU AU2021410006A patent/AU2021410006A1/en not_active Abandoned
- 2021-12-22 WO PCT/US2021/064954 patent/WO2022140605A2/en not_active Ceased
- 2021-12-22 US US18/268,393 patent/US20240301362A1/en active Pending
- 2021-12-22 TW TW110148211A patent/TW202242119A/zh unknown
- 2021-12-22 KR KR1020237024787A patent/KR20230144530A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202242119A (zh) | 2022-11-01 |
| US20240301362A1 (en) | 2024-09-12 |
| AU2021410006A1 (en) | 2023-07-13 |
| CA3204988A1 (en) | 2022-06-30 |
| IL303901A (en) | 2023-08-01 |
| EP4267159A2 (en) | 2023-11-01 |
| JP2024501841A (ja) | 2024-01-16 |
| KR20230144530A (ko) | 2023-10-16 |
| EP4267159A4 (en) | 2025-05-07 |
| WO2022140605A3 (en) | 2022-08-18 |
| WO2022140605A2 (en) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001372A1 (es) | Construcciones para terapia génica con microdistrofina y uso de las mismas. | |
| BR112021026832A2 (pt) | Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada | |
| CY1123413T1 (el) | Φακοϊικοι φορεις | |
| UY40421A (es) | Formulación que comprende una enzima que cataliza la producción de óxido nítrico | |
| MX2024005677A (es) | Receptores de celulas t que reconocen p53 mutado. | |
| ATE497785T1 (de) | Sequenzielle freisetzung immunogener moleküle über adenoviren und adeno-assoziierte viren vermittelte abgaben | |
| IL277587A (en) | Expression vectors for chimeric phagocytic receptors, genetically modified host cells and uses thereof | |
| WO2015168547A3 (en) | In vivo gene engineering with adenoviral vectors | |
| MX2023000156A (es) | Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina. | |
| EP4316500A3 (en) | Bio-production of lentiviral vectors | |
| MX2018003062A (es) | Receptores de celula t que reconocen kras mutante restringido en hla-cw8. | |
| ZA202001586B (en) | Variant rnai | |
| MX2023007507A (es) | Vectores auxiliares adenovirales del serotipo 35. | |
| MX2017000107A (es) | Sistema para anuloplastia. | |
| MX2020000676A (es) | Composiciones y metodos para tratar beta-hemoglobinopatias. | |
| EA202090700A1 (ru) | Компетентные по репликации аденовирусные векторы | |
| EP4055174A4 (en) | TRANSGENIC CASSETTES, AAV VECTORS AND AAV VECTORS FOR EXPRESSING HUMAN CODON-OPTIMIZED SLCA1 | |
| CL2020001850A1 (es) | Vectores inmunoevasivos y uso para terapia génica. | |
| FR3054841B1 (fr) | Systeme d'expression baculovirus | |
| BR112023004874A2 (pt) | Construções de ácido nucléico, vetores virais e partículas virais | |
| AR114989A1 (es) | Vectores adenovirales con dos casetes de expresión | |
| BR112023024205A2 (pt) | Sistemas de produção do vetor viral, células modificadas para produção do vetor viral, e métodos de uso dos mesmos | |
| MX2023007375A (es) | Parapoxvirus modificado que tiene inmunogenicidad incrementada. | |
| NO20085201L (no) | Rekombinante novirhabdoviruser og deres anvendelse | |
| MX2023007376A (es) | Parapoxvirus modificado que tiene inmunogenicidad incrementada. |